IBCL-485 A Phase III, Randomized, Double-Blind, Study of Tazemetostat or Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory Follicular Lymphoma
- Resource Type
- Abstract
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia September 2023 23 Supplement 1:S454-S455 - Subject
- Language
- ISSN
- 2152-2650